Cargando…

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection

The prenylation inhibitor lonafarnib (LNF) is a potent antiviral agent providing a breakthrough for the treatment of hepatitis delta virus (HDV). The current study used a maximum likelihood approach to model LNF pharmacokinetic (PK) and pharmacodynamic (PD) parameters and predict the dose needed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canini, Laetitia, Koh, Christopher, Cotler, Scott J., Uprichard, Susan L., Winters, Mark A., Han, Ma Ai Thanda, Kleiner, David E., Idilman, Ramazan, Yurdaydin, Cihan, Glenn, Jeffrey S., Heller, Theo, Dahari, Harel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721397/ https://www.ncbi.nlm.nih.gov/pubmed/29404459 http://dx.doi.org/10.1002/hep4.1043

Ejemplares similares

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
por: Canini, Laetitia, et al.
Publicado: (2017)

The course of COVID-19 infection in patients with chronic hepatitis B and Delta
por: Parlar, Yavuz Emre, et al.
Publicado: (2022)

Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
por: Malespin, Miguel, et al.
Publicado: (2016)

Correction to: Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Developing New Therapies for Delta Hepatitis: The Race Is On
por: Gençdal, Genco, et al.
Publicado: (2021)

Lonafarnib Is a Potential Inhibitor for Neovascularization
por: Sun, Linlin, et al.
Publicado: (2015)

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection
por: Tsuge, Masataka, et al.
Publicado: (2019)

Discovery of Lonafarnib-Like Compounds: Pharmacophore Modeling and Molecular Dynamics Studies
por: Rampogu, Shailima, et al.
Publicado: (2020)

Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic
por: Maya, Stephanie, et al.
Publicado: (2023)

Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum
por: Kushner, Tatyana, et al.
Publicado: (2023)

Accounting for Space — Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models
por: Kumberger, Peter, et al.
Publicado: (2018)

The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country
por: Toy, Mehlika, et al.
Publicado: (2012)

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg
por: Shekhtman, Louis, et al.
Publicado: (2020)

Recent advances in managing hepatitis D
por: Yurdaydin, Cihan
Publicado: (2017)

Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome
por: Murtada, Sae-Il, et al.
Publicado: (2023)

Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia
por: Ahmed, Amir I. A., et al.
Publicado: (2015)

Modeling Challenges of Ebola Virus–Host Dynamics during Infection and Treatment
por: Chertow, Daniel S., et al.
Publicado: (2020)

Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells
por: Arnold, Rouven, et al.
Publicado: (2021)

Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
por: Goyal, Ashish, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance
por: Shekhtman, Louis, et al.
Publicado: (2021)

ATA Index: A novel score for predicting fibrosis stage in chronic viral hepatitis
por: Yarkan Tugsal, Handan, et al.
Publicado: (2021)

Chronic hepatitis delta: A state-of-the-art review and new therapies
por: Gilman, Christy, et al.
Publicado: (2019)

Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago
por: Echevarria, Desarae, et al.
Publicado: (2015)

Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells
por: Wang, Jialiang, et al.
Publicado: (2017)

Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced Osteolysis
por: Huang, Linke, et al.
Publicado: (2022)

Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure
por: Hershkovich, Leeor, et al.
Publicado: (2023)

HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection Dynamics
por: Durso-Cain, Karina, et al.
Publicado: (2021)

A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection
por: Lempp, Florian A., et al.
Publicado: (2021)

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
por: Sandmann, Lisa, et al.
Publicado: (2021)

Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy
por: Hercun, Julian, et al.
Publicado: (2023)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ak85huk1h7s6gi0utq6bbc6eam